

Learn how to check if a pharmacy has Dexmethylphenidate XR in stock without calling around. Use Medfinder, pharmacy apps, and other tools to save time.
If you've been prescribed Dexmethylphenidate XR (Focalin XR), you may already know how frustrating it can be to find it in stock. The ongoing ADHD medication shortage has left many pharmacies without reliable supply, and calling pharmacy after pharmacy wastes hours you don't have.
The good news: there are ways to check stock without picking up the phone. Here's how.
Dexmethylphenidate XR has been on the ASHP drug shortage list since 2023. Multiple manufacturers have various strengths on back order, and DEA production quota limits combined with rising ADHD diagnosis rates have kept supply tight through 2026.
As a Schedule II controlled substance, pharmacies face extra restrictions on how much they can order. A pharmacy might have one strength in stock but not another, or be completely out of generic Dexmethylphenidate ER while still carrying brand-name Focalin XR.
For the full story, read our article on why Dexmethylphenidate XR is so hard to find.
Medfinder was built specifically for this problem. It shows you which pharmacies near you have Dexmethylphenidate XR in stock — in real time. Simply enter the medication name and your location, and you'll see a list of pharmacies with current availability.
This is especially useful during shortages because Medfinder aggregates data across multiple pharmacy locations, saving you from calling each one individually.
Many major pharmacy chains have mobile apps or websites that let you check medication availability:
Keep in mind that pharmacy apps don't always show real-time inventory — especially for controlled substances. They work best for checking if your existing prescription is ready, rather than finding new stock.
While GoodRx is primarily a coupon and price-comparison tool, it can also give you a sense of which pharmacies have Dexmethylphenidate XR available. If a pharmacy shows a price for the medication, it's more likely to be in stock — though this isn't guaranteed.
Generic Dexmethylphenidate ER prices on GoodRx typically start around $40 to $150 per month for 30 capsules, depending on the dose and pharmacy. Brand-name Focalin XR runs $250 to $490 per month.
Don't overlook independent pharmacies in your area. They sometimes have more flexibility in ordering controlled substances and may have stock when the big chains are out. Many independent pharmacies have their own websites or Facebook pages where they post stock updates.
Sometimes a phone call is still the best option. Here are tips to make it more efficient:
When you locate a pharmacy with Dexmethylphenidate XR available, act quickly. Stock can change within hours during shortages. Here's what to do:
Remember, Schedule II prescriptions generally cannot be transferred between pharmacies. If your prescription was sent to a pharmacy that's out of stock, your doctor may need to cancel it and send a new one to the pharmacy that has it.
Don't forget to check for savings. Generic Dexmethylphenidate ER with a coupon can save you hundreds compared to paying cash for brand-name Focalin XR. Check our full guide on coupons, discounts, and savings programs for Dexmethylphenidate XR.
Finding Dexmethylphenidate XR during a shortage is stressful, but you don't have to spend your day on the phone. Start with Medfinder for real-time stock information, check pharmacy apps, and use coupon tools like GoodRx to compare prices. If all else fails, a well-prepared phone call to a few pharmacies can get you the answers you need quickly.
The shortage won't last forever, but while it does, these tools can make the process much easier.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.